171 related articles for article (PubMed ID: 24365460)
1. Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia.
Desroches J; Bouchard JF; Gendron L; Beaulieu P
Neuroscience; 2014 Mar; 261():23-42. PubMed ID: 24365460
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal RGS4 inhibitor, CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test.
Yoon SY; Woo J; Park JO; Choi EJ; Shin HS; Roh DH; Kim KS
Anesth Analg; 2015 Mar; 120(3):671-677. PubMed ID: 25695583
[TBL] [Abstract][Full Text] [Related]
3. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
Smith PA; Selley DE; Sim-Selley LJ; Welch SP
Eur J Pharmacol; 2007 Oct; 571(2-3):129-37. PubMed ID: 17603035
[TBL] [Abstract][Full Text] [Related]
4. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
5. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain.
Yuill MB; Hale DE; Guindon J; Morgan DJ
Mol Pain; 2017; 13():1744806917728227. PubMed ID: 28879802
[TBL] [Abstract][Full Text] [Related]
6. Opioid-sparing effects of cannabinoids on morphine analgesia: participation of CB
Chen X; Cowan A; Inan S; Geller EB; Meissler JJ; Rawls SM; Tallarida RJ; Tallarida CS; Watson MN; Adler MW; Eisenstein TK
Br J Pharmacol; 2019 Sep; 176(17):3378-3389. PubMed ID: 31218677
[TBL] [Abstract][Full Text] [Related]
7. Dual allosteric modulation of opioid antinociceptive potency by α2A-adrenoceptors.
Chabot-Doré AJ; Millecamps M; Naso L; Devost D; Trieu P; Piltonen M; Diatchenko L; Fairbanks CA; Wilcox GL; Hébert TE; Stone LS
Neuropharmacology; 2015 Dec; 99():285-300. PubMed ID: 26254859
[TBL] [Abstract][Full Text] [Related]
8. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
Tham SM; Angus JA; Tudor EM; Wright CE
Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
[TBL] [Abstract][Full Text] [Related]
9. Treatment with a heme oxygenase 1 inducer enhances the antinociceptive effects of µ-opioid, δ-opioid, and cannabinoid 2 receptors during inflammatory pain.
Carcolé M; Castany S; Leánez S; Pol O
J Pharmacol Exp Ther; 2014 Oct; 351(1):224-32. PubMed ID: 25204546
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists.
Altun A; Yildirim K; Ozdemir E; Bagcivan I; Gursoy S; Durmus N
J Physiol Sci; 2015 Sep; 65(5):407-15. PubMed ID: 25894754
[TBL] [Abstract][Full Text] [Related]
12. dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice.
Wu HE; Sun HS; Terashivili M; Schwasinger E; Sora I; Hall FS; Uhl GR; Tseng LF
Eur J Pharmacol; 2006 Feb; 531(1-3):103-7. PubMed ID: 16445907
[TBL] [Abstract][Full Text] [Related]
13. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats.
Wang YX; Gao D; Pettus M; Phillips C; Bowersox SS
Pain; 2000 Feb; 84(2-3):271-81. PubMed ID: 10666532
[TBL] [Abstract][Full Text] [Related]
14. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests.
Burgos E; Pascual D; Martín MI; Goicoechea C
Eur J Pain; 2010 Jan; 14(1):40-8. PubMed ID: 19318283
[TBL] [Abstract][Full Text] [Related]
16. Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate.
La Porta C; Bura SA; Aracil-Fernández A; Manzanares J; Maldonado R
Pain; 2013 Jan; 154(1):160-174. PubMed ID: 23199705
[TBL] [Abstract][Full Text] [Related]
17. Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor.
Pacheco Dda F; Klein A; Perez AC; Pacheco CM; de Francischi JN; Reis GM; Duarte ID
Br J Pharmacol; 2009 Sep; 158(1):225-31. PubMed ID: 19594755
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal atipamezole augments the antinociceptive effect of morphine in rats.
Lilius TO; Rauhala PV; Kambur O; Rossi SM; Väänänen AJ; Kalso EA
Anesth Analg; 2012 Jun; 114(6):1353-8. PubMed ID: 22556211
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602
[TBL] [Abstract][Full Text] [Related]
20. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors.
Valverde O; Ledent C; Beslot F; Parmentier M; Roques BP
Eur J Neurosci; 2000 Feb; 12(2):533-9. PubMed ID: 10712632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
